Phase Ib dose finding and proof-of-concept trial of savolitinib in combination with durvalumab [MEDI-4736] as a second-line treatment in patients with clear renal cell carcinoma

Trial Profile

Phase Ib dose finding and proof-of-concept trial of savolitinib in combination with durvalumab [MEDI-4736] as a second-line treatment in patients with clear renal cell carcinoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2016

At a glance

  • Drugs Savolitinib (Primary) ; Durvalumab
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Proof of concept
  • Most Recent Events

    • 02 Aug 2016 Status changed from planning to recruiting, according to a Chi-Med media release.
    • 15 Oct 2015 New trial record
    • 13 Oct 2015 According to a Chi-Med media release, this trial is expected to be initiated by the end of 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top